25 May 2013
Keywords: mircera, maintains, hb, levels, high-risk, patients, swiss
Article | 09 July 2007
Swiss drug major Roche says that an analysis of two large-scale Phase III maintenance studies of once-monthly Micera, its continuous
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 July 2007
24 May 2013
© 2013 thepharmaletter.com